profile B24 tious diseases. mAbsto fight infecrace to develop next-generation in mAbdevelopment line now representing areas oneofthemostactive But withtheanti-infective mAbdevelopment pipe Biologics’ Trogarzo for (ibalizumab-uiyk) HIV in 2018. for Merck’s2016, respectively; Zinplava (bezlotoxumab) aximab), both for inhalational anthrax,in 2012 and Abthrax (raxibacumab)andElusys’ Anthim(obiltox izing mAbs have been approved: GlaxoSmithKline’s onlyfourin newborns, otheranti-infective neutral virusinfection the prevention syncytial ofrespiratory approval ofMedImmune’s Synagis (palivizumab)for of anepidemic.” have thepotentialinterventions to alter thecourse tive, highlyspecificpreventive andtherapeutic development and strategic deployment of effec the Diseases, inarecentInfectious in perspective ofAllergydirector oftheNationalInstitute and difficult andprolonged,” argued Anthony Fauci, vaccine development for pathogensmay new be disease (EID)outbreaks, inwhichtheprocess of ofemerging inthecontext infectiousticularly onthefieldofinfectious diseases,impact par in mAbdevelopment couldhave anenormous and therapeutics. thatareity idealfor thedevelopment ofdiagnostics ranges ofspecificitiesandminimalimmunogenic approach delivers fully humanmAbswithbroad andfungalcells. bacterial full virusparticles, This libraries, ofantigen,even againstany against type (10 universal libraries ment offullyhumanantibodies, from thecompany’s in thisspace. YUMAB to expanditsglobalcollaborationnetwork tious diseasesthatprovide anidealenvironment for (DZIF): three leadersinthefightagainstinfec world Centre(DSMZ) andtheGerman for Research Infection of MicroorganismsCollection and Cell Cultures Research (HZI),the Leibniz Institute-German colocated with the HelmholtzCentre ofInfection infectious diseaseresearch hotspot. YUMAB isnow Campus Braunschweig-South,Science Germany’s and researchheadquarters and development labs to anddevelopment, hasrecently relocatedcovery its of fullyhumanmonoclonalantibody(mAb)dis Biotechnology company YUMAB, aglobalprovider expedited development ofprophylactic andtherapeutic antibodies and vaccines to fight diseases. infectious to Germany’sits headquarters research hotspot of infectious for andis advancing the new opportunities YUMAB, a globalprovider of fullyhuman monoclonal antibody discovery and development, hasrelocated antibody and vaccine development anti-infective YUMAB: boosting www.yumab.com YUMAB GmbH Since the US Food andDrugAdministration’s 1998 conceptual“Recent and technological advances YUMAB’s antibodyplatform enablesthedevelop Clostridium difficile |June2018 | New England Journal ofMedicine EnglandJournal New

biopharmadealmakers.nature.com infection in2016;and TaiMed 2 11 , YUMAB ispoisedto jointhe ) andfrom patient-derived 1 . “The rapid . “The ------©

Aspergillus fumigatus virus; andsuper-humanized antibodies against cis toxins from and Western equineencephalitis viruses, and bacterial neutralizing antibodiesagainstHIV, Ebola, Venezuelan Hust, have longtrackrecords inthedevelopment of vaccines anddrugs( forantibodies ofbroad specificity better diagnostics, tion results inhighsuccess rates and can identify to non-neutralizing epitopes. Moreover, invitro selec response, whichcanmisguideantibodyresponses potential epitope preference by thehostimmune covery. animalimmunizationeliminates Bypassing infected or vaccinated patients for initial in vitro dis repertoire, generated from orimmune libraries which represent theentire naturalhumanantibody robust andrapidantibodydevelopment platforms. conjugates, allofwhichrequireand antibody–drug get crucialpathogenepitopes, oligoclonalantibodies Emerging strategies includetheuseofmAbsthattar and pathogenic mechanisms challenge efficacy. variability, mutational resistance, multiple entry andtherapeutically,phylactically butpathogen to stop orprevent aninfection. vaccinedesign, requiring otherstrategies imperfect ous immunity, outbreaks ofemerging pathogensor can fail owing to immunosuppression, lack of previ achieves similarprotection. However, immunization fail. Prophylactic vaccinationmimicsaninfection and ond lineofdefense ifinnate immunemechanisms B cells thatcanprovide lifelong asasec immunity system generates T cells andantibody-producing thefightagainstpathogens, theadaptiveIn immune disease infectious in edge YUMAB The development platform. fully humanmAb andtarget discovery and Fig. 1| Drivinganti-infective mAbs with YUMAB’s Pathogens 2 Two YUMAB founders, Stefan DübelandMichael YUMAB useseitheritsuniversal antibodylibraries, mAbs offer to fightinfections pro thepossibility 0 ; protective antibodies against wild-type Marburg ; protective Marburg antibodiesagainstwild-type 1 8

M a c m Clostridium botulinum i l l YUMAB a n

P u b ® and l Fig. 1 PLATFORM i s h e r Clostridium diphtheria s

). L i m i t e and d .

A l l

Bacillus anthra r i Diagnostics Diagnostics g h Therapeutics Therapeutics t s r e Vaccines toxins. s e r v e d ------. ADVERTISER RETAINS FORCONTENTADVERTISER SOLERESPONSIBILITY needed for novel prophylactic ortherapeuticstrate ment program, atany stage, andwiththeproperties ofmAbdevelop to thespecificneedsofany kind human mAbsdeveloped at YUMAB canbetailored from basicresearch to clinicaltranslation. The fully to drive infectious diseaseprogramsideal partner anddevelopment platform makes ery YUMAB an disease and an advanced fully human mAb discov 1. level.” thesedevelopments to thenext can take world’s hotspotsfor infectious diseaseresearch, we development. With ourrelocation to oneofthe and identifynovel immunogenictargets for vaccine develop advanced antibodies from patient libraries of years of exposure to pathogens. We canrapidly drug candidates thathave evolved over millions “YUMAB’s platform provides accessto biological based solutionsintheinfectious diseasespace. is well suited for thedevelopment ofnovel mAb- ofitsantibodytechnologymaximizes and theimpact therapeutic mAbleadcandidates inotherareas. platform, whichhasalready generated fullyhuman and lead optimization with its antibody discovery ment ofitscustomers’ anti-infective mAbpipelines YUMAB iscommitted to accelerating thedevelop diseases infectious to fight Partnering gies againstinfectious diseases. 2. The combination of deep expertise ininfectious The combinationofdeepexpertise According to YUMAB’s CEO, Thomas Schirrmann, YUMAB’s flexibleand broad collaborationstrategy Marston, H. D., Paules, C. I. & Fauci, A. S. contact programs-says-gbi-research (2017). pipeline-for-monoclonal-antibodies-encompasses-over-2800- http://gbiresearch.com/media-center/press-releases/industry- Encompasses 2,800Programs, Over saysGBIResearch. GBI Research. 1469–1472 (2018). Email: [email protected] Tel: 531 +49 4811 700 Braunschweig, Germany GmbH YUMAB CEO Schirrmann, Thomas Industry Pipeline forMonoclonalAntibodiesIndustry ADVERTISEMENT FEATUREADVERTISEMENT N. Engl. J. Med.

378 - - - - ,